



BOB RILEY
Governor

Alabama Medicaid Agency

501 Dexter Avenue
P.O. Box 5624
Montgomery, Alabama 36103-5624

www.medicaid.state.al.us
e-mail: almedicaid@medicaid.state.al.us
Telecommunication for the Deaf: 1-800-253-0799
334-242-5000 1-800-362-1504



CAROL A. HERRMANN-STECKEL, MPH
Commissioner

April 7, 2006

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with formal written notification of an upcoming meeting of the Alabama Medicaid Pharmacy & Therapeutics (P&T) Committee, to be held on **Wednesday, May 24, 2006**. This meeting may involve review of one or more of your company's drug products. Please note: this meeting will be held at the Alabama State Capitol Auditorium located in Montgomery, Alabama, and will begin at 9:00 a.m. All meetings of this committee are open to the public.

The following is a list of new drugs and drug classes scheduled for review at this meeting:

NEW DRUG REVIEWS	
1. Asmanex Twisthaler ® - AHFS 680400 Adrenals	
2. Byetta ® - AHFS 682092 Antidiabetic Agents, Miscellaneous	
3. Symlin ® - AHFS 682092 Antidiabetic Agents, Miscellaneous	

DRUG CLASS REVIEWS	
1. Central Alpha-Agonists - AHFS 240816	9. Angiotensin-Converting Enzyme Inhibitors AHFS 243204
2. Direct Vasodilators - AHFS 240820	10. Angiotensin II Receptor Antagonists — AHFS 243208
3. Peripheral Adrenergic Inhibitors - AHFS 240832	11. Mineralocorticoid Receptor Antagonists - AHFS 243220
4. Hypotensive Agents, Miscellaneous - AHFS 240892	12. Diuretics - AHFS 402800
5. Alpha-Adrenergic Blocking Agents - AHFS 242000	13. Potassium-Sparing Diuretics - AHFS 402810
6. Beta-Adrenergic Blocking Agents - AHFS 242400	
7. Calcium-Channel Blocking Agents, Dihydropyridines - AHFS 242808	
8. Calcium-Channel Blocking Agents, Miscellaneous AHFS 242892	

As you may be aware, manufacturers whose products are scheduled for review are allowed the opportunity to provide written clinical comments for distribution to the Medicaid P&T Committee members prior to the meeting. For products slated for P&T review, manufacturers are also allowed the opportunity to make brief (no more than 5 minutes) oral summary presentations of product clinical data to the Medicaid P&T Committee on the day of the meeting.

Approval for distribution of written clinical comments to P&T members and approval of oral presentation summary submissions are based strictly upon the following guidelines:

Written Comments:

- 1) All written comments must be mailed to Medicaid's Clinical Contractor, *MedMetrics Health Partners*, Attn: *AL Medicaid P&T Support (1-800-644-4079)*; 100 Century Drive; Worcester, MA 01606, and received no later than **Wednesday, May 3, 2006**. Packages must be properly labeled "Attn: *AL Medicaid P&T Support*" and include the full contact information of the designated manufacturer's point of contact.
- 2) Written comments should be limited to clinical information only and **must not contain any reference to cost**.
- 3) Submissions are limited to hard-copy written form only (not CD-ROM, e-mail, etc.).
- 4) Manufacturers must provide **20 copies** of written comments upon submission to *MedMetrics*.

Our Mission - to provide an efficient and effective system of financing health care for our beneficiaries.

Oral Presentation Summaries:

- 1) Written notification of your intent to make an oral presentation must be mailed to *MedMetrics Health Partners, Attn: AL Medicaid P&T Support (1-800-644-4079); 100 Century Drive; Worcester, MA 01606*), and received no later than **Wednesday, May 3, 2006**. Submissions must be properly labeled "*Attn: AL Medicaid P&T Support*" and include the full contact information of the designated manufacturer's point of contact.
- 2) Oral presentations must also be limited to clinical information only and **must not contain any reference to cost**.
- 3) Submissions are limited to hard-copy written form only (not CD-ROM, e-mail, etc.).
- 4) One copy of a **one-page summary** of the material to be presented must be received along with the written notification. (Please note: this should be a single-sided document only; do not include references or any other information on the reverse side.)

Failure to abide by all of these requirements upon submission will result in a rejection of the clinical comments and/or oral presentation summaries in their entirety. Manufacturers are also encouraged to submit information as soon as possible. Waiting until just days prior to the deadline for submission of these materials may not allow time for corrections and resubmission prior to the deadline. No submissions or resubmissions will be accepted after the designated deadline.

Please refer to the Medicaid web-site for additional information related to presentations, timelines, clinical comment submissions, and/or submission of volume discounts. Volume discount submissions should not be included in this submission to MedMetrics, as these will not be reviewed by MedMetrics nor forwarded to Alabama Medicaid. If you should have additional questions regarding this notice or if you have received this letter and are no longer the appropriate contact, please notify the Medicaid Pharmacy Program at (334) 242-5050.

Sincerely,



Bakeba R. Thomas
Administrator, Pharmacy Clinical Support Unit